|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
|
WO1997009976A2
(en)
|
1995-09-01 |
1997-03-20 |
Washington University |
Method of reducing neurotoxic injury with zinc chelators
|
|
PL329070A1
(en)
|
1996-03-22 |
1999-03-15 |
Du Pont Pharm Co |
Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
|
|
CA2290992C
(en)
|
1997-06-02 |
2008-02-12 |
Janssen Pharmaceutica N.V. |
(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
|
|
EP1003514A4
(en)
|
1997-07-25 |
2000-10-11 |
Merck & Co Inc |
CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
|
|
DE69833036T2
(de)
|
1997-09-30 |
2006-06-22 |
Daiichi Pharmaceutical Co., Ltd. |
Sulfonylderivate
|
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
|
CN1282243A
(zh)
|
1997-12-19 |
2001-01-31 |
武田药品工业株式会社 |
用于拮抗ccr5的含n-酰苯胺衍生物的药物组合物
|
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
JP2003524620A
(ja)
|
1999-03-24 |
2003-08-19 |
アノーメッド インコーポレイティド |
ケモカインレセプター結合複素環化合物
|
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
AU9355101A
(en)
|
2000-09-15 |
2002-03-26 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
|
KR20030034184A
(ko)
|
2000-09-15 |
2003-05-01 |
아노르메드 인코포레이티드 |
케모킨 수용체 결합 헤테로사이클릭 화합물
|
|
IL154227A0
(en)
|
2000-09-15 |
2003-07-31 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
|
AU2001297717B2
(en)
|
2000-12-11 |
2006-02-23 |
Amgen Inc. |
CXCR3 antagonists
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
US6987102B2
(en)
|
2001-07-31 |
2006-01-17 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
|
US6825351B2
(en)
|
2001-09-12 |
2004-11-30 |
Anormed, Inc. |
Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
|
|
RU2325387C2
(ru)
|
2001-12-21 |
2008-05-27 |
Анормед Инк. |
Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
|
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
|
BRPI0313733A8
(pt)
|
2002-08-14 |
2016-08-16 |
Atugen Ag |
Uso da proteína n beta cinase
|
|
JP4666256B2
(ja)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
|
CA2520259A1
(en)
|
2003-04-11 |
2004-10-28 |
Anormed Inc. |
Cxcr4 chemokine receptor binding compounds
|
|
CA2517077C
(en)
|
2003-04-22 |
2013-03-12 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
|
ES2614508T3
(es)
|
2004-03-15 |
2017-05-31 |
Genzyme Corporation |
Proceso para la síntesis de un antagonista de CXCR4
|
|
CA2561718A1
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
|
MX2007001514A
(es)
|
2004-08-02 |
2007-03-27 |
Smithkline Beecham Corp |
Compuestos quimicos.
|
|
BRPI0514438A
(pt)
|
2004-08-16 |
2008-06-10 |
Smithkline Beecham Corp |
composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de uma condição ou doença moduladas por um receptor de quimiocina, e, processo para a preparação do composto
|
|
MX2007002679A
(es)
|
2004-09-02 |
2007-05-16 |
Smithkline Beecham Corp |
Compuestos quimicos.
|
|
WO2006036816A2
(en)
|
2004-09-24 |
2006-04-06 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
WO2006096444A2
(en)
|
2005-03-04 |
2006-09-14 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
ATE476529T1
(de)
|
2005-07-08 |
2010-08-15 |
Siemens Healthcare Diagnostics |
Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
|
|
EP1904501A2
(en)
|
2005-07-11 |
2008-04-02 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
CA2617436A1
(en)
|
2005-08-02 |
2007-02-08 |
Ineos Europe Limited |
Diene polymerisation catalysts comprising two or more transition metals
|
|
EP1919872A4
(en)
|
2005-08-31 |
2009-08-05 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
|
PT1961744E
(pt)
|
2005-11-18 |
2013-05-15 |
Ono Pharmaceutical Co |
Composto que contém um grupo básico e sua utilização
|
|
AR063656A1
(es)
|
2005-11-30 |
2009-02-11 |
Schering Corp |
Composiciones que comprenden una combinacion de antagonistas de ccr5 y cxcr4
|
|
PE20070946A1
(es)
|
2006-01-25 |
2007-10-16 |
Smithkline Beecham Corp |
COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
|
|
EP1984375A2
(en)
|
2006-01-25 |
2008-10-29 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
|
RU2420284C2
(ru)
|
2006-06-12 |
2011-06-10 |
Пфайзер Продактс Инк. |
Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич
|
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
|
CN101855222A
(zh)
|
2007-05-10 |
2010-10-06 |
通用电气健康护理有限公司 |
对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
|
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
|
JP5690715B2
(ja)
|
2008-03-28 |
2015-03-25 |
アルテイリス・セラピユーテイクス |
ケモカイン受容体調節因子
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
JP2010016628A
(ja)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
|
CA2745295C
(en)
|
2008-12-09 |
2017-01-10 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
CN102481261B
(zh)
|
2009-09-28 |
2014-12-31 |
赞布里国际有限公司 |
药物组合物
|
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
|
US20110295365A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
|
WO2012047339A2
(en)
|
2010-06-28 |
2012-04-12 |
The General Hospital Corporation |
Anti-cxcr4 as a sensitizer to cancer therapeutics
|
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
|
US9267934B2
(en)
|
2010-10-26 |
2016-02-23 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
|
AU2011336397B2
(en)
|
2010-12-03 |
2016-12-15 |
Emory University |
Chemokine CXCR4 receptor modulators and uses related thereto
|
|
US8435993B2
(en)
|
2010-12-07 |
2013-05-07 |
Philadelphia Health And Education Corporation |
Methods of inhibiting metastasis from cancer
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
AU2012206945B2
(en)
|
2011-01-11 |
2015-02-19 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
|
KR20200016407A
(ko)
|
2011-05-16 |
2020-02-14 |
젠자임 코포레이션 |
Cxcr4 길항제의 용도
|
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA2860995A1
(en)
|
2012-01-12 |
2013-07-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
|
AU2013347838A1
(en)
|
2012-11-26 |
2015-06-11 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarker compositions and methods
|
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
|
EP3473299A1
(en)
|
2013-06-05 |
2019-04-24 |
Salk Institute for Biological Studies |
Vitamin d receptor agonists to treat diseases involving cxcl12 activity
|
|
JP2016527303A
(ja)
|
2013-08-05 |
2016-09-08 |
ケンブリッジ エンタープライズ リミテッド |
がん免疫療法におけるcxcr4シグナル伝達の阻害
|
|
JP2016529293A
(ja)
*
|
2013-08-27 |
2016-09-23 |
ギリアド ファーマセット エルエルシー |
2つの抗ウイルス化合物の組合せ製剤
|
|
EP3044338B1
(en)
|
2013-09-12 |
2021-11-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
|
EA201690912A1
(ru)
|
2013-11-05 |
2016-10-31 |
Когнейт Биосервисис, Инк. |
Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
|
|
US10280183B2
(en)
|
2014-03-18 |
2019-05-07 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
US9394305B2
(en)
|
2014-06-23 |
2016-07-19 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
|
|
ES2909957T3
(es)
|
2014-07-16 |
2022-05-11 |
Transgene |
Virus oncolítico para la expresión de moduladores de puntos de control inmunitarios
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
BR112017026189A2
(pt)
|
2015-06-12 |
2018-08-14 |
Bristol Myers Squibb Co |
tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
|
|
NZ740616A
(en)
|
2015-09-14 |
2023-05-26 |
Infinity Pharmaceuticals Inc |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
|
WO2017106332A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
JP6864296B2
(ja)
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
|
PL3393468T3
(pl)
|
2015-12-22 |
2023-01-23 |
X4 Pharmaceuticals, Inc. |
Metody leczenia niedoboru odporności
|
|
JP2019502741A
(ja)
|
2016-01-22 |
2019-01-31 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置するための方法
|
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
EP3443013B1
(en)
|
2016-04-14 |
2025-01-22 |
Creatv Microtech, Inc. |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
JP7084624B2
(ja)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
|
CN110996952A
(zh)
|
2017-06-21 |
2020-04-10 |
X4 制药有限公司 |
用于治疗癌症的方法
|
|
WO2019094392A1
(en)
|
2017-11-07 |
2019-05-16 |
X4 Pharmaceuticals, Inc. |
Cancer biomarkers and methods of use thereof
|
|
US20210009557A1
(en)
|
2017-12-19 |
2021-01-14 |
X4 Pharmaceuticals, Inc. |
Acyclic cxcr4 inhibitors and uses thereof
|
|
JP2021521439A
(ja)
|
2018-04-13 |
2021-08-26 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がん血清バイオマーカーおよびその使用方法
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|